The Conversation Has Changed For Stage III Melanoma
Stage III Melanoma—High Risk for Recurrence and (Now) Multiple Options Stage III adjuvant treatment options were for many years limited…
Melanoma Research
06/11/2019
The Conversation Has Changed For Stage III Melanoma
Stage III Melanoma—High Risk for Recurrence and (Now) Multiple Options Stage III adjuvant treatment options were for many years limited…
|
04/04/2019
AIM at Melanoma Opens The First Branch of Fresh Frozen Primary Tissue Bank at the University of Pittsburgh Medical Center (UPMC), Hillman Cancer Center
April 5, 2019 (San Rafael, California)… AIM at Melanoma announces the grand opening of the first branch of the International…
|
|
03/20/2019
Why Fresh-Frozen Primary Tissue is Critically Important in the Fight Against Melanoma
AIM at Melanoma will very soon announce the grand opening of the first branch of the International Tissue Bank Consortium…
|
11/13/2018
Melanoma International Collaborative Adaptive Trials: Progress Report
The first adaptive platform trial in melanoma—and one of the only adaptive platform trials that will be in existence for…
|
|
11/13/2018
The Melanoma Tissue Bank: Progress Report
As we look back through 2018, perhaps the most exciting news from AIM at Melanoma is the progress on what…
|
|
09/04/2018
Q&A With Three Leading Melanoma Specialists
Eric D. Whitman, MD Medical Director, Atlantic Health System Cancer Care Director, Atlantic Melanoma Center Question: Which clinical trials do…
|
04/27/2018
Q&A with Omid Hamid, MD, Director of the Melanoma Center and Phase I Immuno-Oncology Program at The Angeles Clinic and Research Institute
Dr. Omid Hamid is recognized nationally and internationally as a key opinion leader in Immuno-Oncologic Drug Development and Melanoma…
|
Recent Posts
Jan. 14, 2025
Meaning-Centered Psychotherapy: Finding Purpose in the Face of Cancer
Jan. 09, 2025
What Inspires Leading Melanoma Researchers?
Dec. 30, 2024
Jimmy Carter: A Life that Shaped Cancer Treatment and Hope for Melanoma Patients
Dec. 27, 2024
Bristol Myers Squibb Announces Approval for Subcutaneous Nivolumab
Dec. 12, 2024